Open Label, Multicenter, Phase II Study of Patients With Treatment Naïve Metastatic Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases Randomized to Stereotactic Radiosurgery (SRS) and Osimertinib or Osimertinib Alone
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs Osimertinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 01 Nov 2019 Planned End Date changed from 1 Dec 2022 to 1 Apr 2025.
- 01 Nov 2019 Planned primary completion date changed from 1 Dec 2022 to 1 Apr 2025.
- 19 Mar 2019 Status changed from not yet recruiting to recruiting.